Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines.
Child
Child, Preschool
Humans
Antibodies, Viral
Coronavirus 229E, Human
Coronavirus NL63, Human
Coronavirus OC43, Human
COVID-19
/ epidemiology
Philippines
/ epidemiology
Recombinant Proteins
SARS-CoV-2
Seroepidemiologic Studies
Coronavirus Infections
/ epidemiology
Coronavirus
/ genetics
Betacoronavirus
Antibodies, Neutralizing
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 02 2023
09 02 2023
Historique:
received:
28
10
2022
accepted:
30
01
2023
entrez:
9
2
2023
pubmed:
10
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
Four endemic human coronaviruses (HCoV), HCoV-229E, HCoV-NL63, HCoV-HKU1, and HCoV-OC43, are closely related to SARS-CoV-2. These coronaviruses are known to infect humans living in temperate areas, including children under 5 years old; however, the seroprevalence of four HCoVs among children in tropical areas, including the Philippines, remains unclear. This study aimed to assess the prevalence of antibodies against four HCoVs and to determine the reactivity and neutralization of these antibodies against SARS-CoV-2 among children in the Philippines. A total of 315 serum samples collected from 2015 to 2018, before the emergence of SARS-CoV-2, in Biliran island, Philippines, were tested for the presence of antibodies against four HCoVs and SARS-CoV-2 using recombinant spike ectodomain proteins by IgG-enzyme-linked immunosorbent assay (ELISA). Reactivity to and neutralization of SARS-CoV-2 were also investigated. The seroprevalence of the four HCoVs was 63.8% for HCoV-229E, 71.4% for HCoV-NL63, 76.5% for HCoV-HKU1, and 83.5% for HCoV-OC43 by ELISA. Age group analysis indicated that seropositivity to all HCoVs reached 80% by 2-3 years of age. While 69/315 (21.9%) of the samples showed reactive to SARS-CoV-2, almost no neutralization against SARS-CoV-2 was detected using neutralization assay. Reactivity of antibodies against SARS-CoV-2 spike protein obtained by ELISA may not correlate with neutralization capability.
Identifiants
pubmed: 36759702
doi: 10.1038/s41598-023-29072-3
pii: 10.1038/s41598-023-29072-3
pmc: PMC9909632
doi:
Substances chimiques
Antibodies, Viral
0
Recombinant Proteins
0
spike protein, SARS-CoV-2
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2310Informations de copyright
© 2023. The Author(s).
Références
Brian, D. A. & Baric, R. S. Coronavirus genome structure and replication. Curr. Top Microbiol. Immunol. 287, 1–30. https://doi.org/10.1007/3-540-26765-4_1 (2005).
doi: 10.1007/3-540-26765-4_1
pubmed: 15609507
Gorbalenya, A. E., Enjuanes, L., Ziebuhr, J. & Snijder, E. J. Nidovirales: Evolving the largest RNA virus genome. Virus Res. 117, 17–37. https://doi.org/10.1016/j.virusres.2006.01.017 (2006).
doi: 10.1016/j.virusres.2006.01.017
pubmed: 16503362
pmcid: 7114179
Hamre, D. & Procknow, J. J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 121, 190–193. https://doi.org/10.3181/00379727-121-30734 (1966).
doi: 10.3181/00379727-121-30734
pubmed: 4285768
McIntosh, K., Dees, J. H., Becker, W. B., Kapikian, A. Z. & Chanock, R. M. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc. Natl. Acad. Sci. U S A 57, 933–940. https://doi.org/10.1073/pnas.57.4.933 (1967).
doi: 10.1073/pnas.57.4.933
pubmed: 5231356
pmcid: 224637
van der Hoek, L. et al. Identification of a new human coronavirus. Nat. Med. 10, 368–373. https://doi.org/10.1038/nm1024 (2004).
doi: 10.1038/nm1024
pubmed: 15034574
pmcid: 7095789
Woo, P. C. et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884–895. https://doi.org/10.1128/JVI.79.2.884-895.2005 (2005).
doi: 10.1128/JVI.79.2.884-895.2005
pubmed: 15613317
pmcid: 538593
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814–1820. https://doi.org/10.1056/NEJMoa1211721 (2012).
doi: 10.1056/NEJMoa1211721
pubmed: 23075143
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269. https://doi.org/10.1038/s41586-020-2008-3 (2020).
doi: 10.1038/s41586-020-2008-3
pubmed: 32015508
pmcid: 7094943
Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953–1966. https://doi.org/10.1056/NEJMoa030781 (2003).
doi: 10.1056/NEJMoa030781
pubmed: 12690092
Belouzard, S., Millet, J. K., Licitra, B. N. & Whittaker, G. R. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4, 1011–1033. https://doi.org/10.3390/v4061011 (2012).
doi: 10.3390/v4061011
pubmed: 22816037
pmcid: 3397359
van der Hoek, L. Human coronaviruses: What do they cause?. Antivir. Ther. 12, 651–658 (2007).
doi: 10.1177/135965350701200S01.1
pubmed: 17944272
Pene, F. et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin. Infect. Dis. 37, 929–932. https://doi.org/10.1086/377612 (2003).
doi: 10.1086/377612
pubmed: 13130404
Hajjar, S. A., Memish, Z. A. & McIntosh, K. Middle east respiratory syndrome coronavirus (MERS-CoV): A perpetual challenge. Ann. Saudi Med. 33, 427–436. https://doi.org/10.5144/0256-4947.2013.427 (2013).
doi: 10.5144/0256-4947.2013.427
pubmed: 24188935
pmcid: 6074883
Shao, X., Guo, X., Esper, F., Weibel, C. & Kahn, J. S. Seroepidemiology of group I human coronaviruses in children. J. Clin. Virol. 40, 207–213. https://doi.org/10.1016/j.jcv.2007.08.007 (2007).
doi: 10.1016/j.jcv.2007.08.007
pubmed: 17889596
pmcid: 2100388
Dijkman, R. et al. Human coronavirus NL63 and 229E seroconversion in children. J. Clin. Microbiol. 46, 2368–2373. https://doi.org/10.1128/jcm.00533-08 (2008).
doi: 10.1128/jcm.00533-08
pubmed: 18495857
pmcid: 2446899
Zhou, W., Wang, W., Wang, H., Lu, R. & Tan, W. First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood. BMC Infect. Dis. 13, 433. https://doi.org/10.1186/1471-2334-13-433 (2013).
doi: 10.1186/1471-2334-13-433
pubmed: 24040960
pmcid: 3848659
Lu, L. et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis. J. Infect. 81, e18–e25. https://doi.org/10.1016/j.jinf.2020.07.002 (2020).
doi: 10.1016/j.jinf.2020.07.002
pubmed: 32634459
pmcid: 7334925
Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch. Dis. Child https://doi.org/10.1136/archdischild-2020-320338 (2020).
doi: 10.1136/archdischild-2020-320338
pubmed: 33262177
Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339–1343. https://doi.org/10.1126/science.abe1107 (2020).
doi: 10.1126/science.abe1107
pubmed: 33159009
pmcid: 7857411
Woudenberg, T. et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine 70, 103495. https://doi.org/10.1016/j.ebiom.2021.103495 (2021).
doi: 10.1016/j.ebiom.2021.103495
pubmed: 34304047
pmcid: 8299153
Chan, C. M. et al. Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus. J. Clin. Virol. 45, 54–60. https://doi.org/10.1016/j.jcv.2009.02.011 (2009).
doi: 10.1016/j.jcv.2009.02.011
pubmed: 19342289
pmcid: 7108224
Luo, Y. et al. Age-related seroprevalence trajectories of seasonal coronaviruses in children including neonates in Guangzhou, China. Int. J. Infect. Dis. 127, 26–32. https://doi.org/10.1016/j.ijid.2022.11.044 (2022).
doi: 10.1016/j.ijid.2022.11.044
pubmed: 36481488
pmcid: 9721286
Tanunliong, G. et al. Age-associated seroprevalence of coronavirus antibodies: Population-based serosurveys in 2013 and 2020, British Columbia, Canada. Front. Immunol. 13, 836449. https://doi.org/10.3389/fimmu.2022.836449 (2022).
doi: 10.3389/fimmu.2022.836449
pubmed: 35401521
pmcid: 8984254
Kosai, H. et al. Incidence and risk factors of childhood pneumonia-like episodes in Biliran Island, Philippines-a community-based study. PLoS ONE 10, 80125009. https://doi.org/10.1371/journal.pone.0125009 (2015).
doi: 10.1371/journal.pone.0125009
Tamminen, K., Salminen, M. & Blazevic, V. Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults. Clin. Immunol. (Orlando, Fla.) 229, 108782. https://doi.org/10.1016/j.clim.2021.108782 (2021).
doi: 10.1016/j.clim.2021.108782
Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N. Engl. J. Med. 388, 183–185. https://doi.org/10.1056/NEJMc2214293 (2023).
doi: 10.1056/NEJMc2214293
pubmed: 36546661
Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 387, 86–88. https://doi.org/10.1056/NEJMc2206576 (2022).
doi: 10.1056/NEJMc2206576
pubmed: 35731894
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280.e278. https://doi.org/10.1016/j.cell.2020.02.052 (2020).
doi: 10.1016/j.cell.2020.02.052
pubmed: 32142651
pmcid: 7102627
Wells, D. A. et al. Human seasonal coronavirus neutralisation and COVID-19 severity. J. Med. Virol. https://doi.org/10.1002/jmv.27937 (2022).
doi: 10.1002/jmv.27937
pubmed: 35715381
pmcid: 9349487
Dhochak, N. et al. Humoral cross-reactivity towards SARS-CoV-2 in young children with acute respiratory infection with low-pathogenicity coronaviruses. J. Clin. Virol. Plus 2, 100061. https://doi.org/10.1016/j.jcvp.2022.100061 (2022).
doi: 10.1016/j.jcvp.2022.100061
pubmed: 35262034
pmcid: 8747779
Ladner, J. T. et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep. Med. 2, 100189. https://doi.org/10.1016/j.xcrm.2020.100189 (2021).
doi: 10.1016/j.xcrm.2020.100189
pubmed: 33495758
pmcid: 7816965
Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97–102. https://doi.org/10.1038/s41586-021-03807-6 (2021).
doi: 10.1038/s41586-021-03807-6
pubmed: 34261126
pmcid: 9282883
Grobben, M. et al. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Elife https://doi.org/10.7554/eLife.70330 (2021).
doi: 10.7554/eLife.70330
pubmed: 34812143
pmcid: 8610423
Song, G. et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat. Commun. https://doi.org/10.1038/s41467-021-23074-3 (2021).
doi: 10.1038/s41467-021-23074-3
pubmed: 34934057
pmcid: 8692330
Ng, K. W. et al. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci. Transl. Med. 14, eabn3715. https://doi.org/10.1126/scitranslmed.abn3715 (2022).
doi: 10.1126/scitranslmed.abn3715
pubmed: 35895836
Watanabe, S. et al. Bat coronaviruses and experimental infection of bats, the Philippines. Emerg. Infect. Dis. 16, 1217–1223. https://doi.org/10.3201/eid1608.100208 (2010).
doi: 10.3201/eid1608.100208
pubmed: 20678314
pmcid: 3298303
Dembele, B. P. P. et al. Aetiology and risks factors associated with the fatal outcomes of childhood pneumonia among hospitalised children in the Philippines from 2008 to 2016: A case series study. BMJ Open 9, e026895. https://doi.org/10.1136/bmjopen-2018-026895 (2019).
doi: 10.1136/bmjopen-2018-026895
pubmed: 30928958
pmcid: 6475207
Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036. https://doi.org/10.1038/s41591-020-0913-5 (2020).
doi: 10.1038/s41591-020-0913-5
pubmed: 32398876
pmcid: 8183627
Nishimura, H., Okamoto, M., Dapat, I., Katsumi, M. & Oshitani, H. Inactivation of SARS-CoV-2 by Catechins from Green Tea. Jpn. J. Infect. Dis. 74, 421–423. https://doi.org/10.7883/yoken.JJID.2020.902 (2021).
doi: 10.7883/yoken.JJID.2020.902
pubmed: 33518628
Fukuta, M. et al. Discrepancies in infectivity of flavivirus and SARS-CoV-2 clinical samples: An improved assay for infectious virus shedding and viremia assessment. Int. J. Environ. Res. Public Health 18, 71. https://doi.org/10.3390/ijerph18189845 (2021).
doi: 10.3390/ijerph18189845